Sangamo Therapeutics Inc
(LTS:0R1D)
$
1.9196
-0.0403 (-2.06%)
Market Cap: 417.29 Mil
Enterprise Value: 405.82 Mil
PE Ratio: 0
PB Ratio: 10.37
GF Score: 34/100 Sangamo Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 01:00PM GMT
Release Date Price:
$4.21
(+0.24%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to introduce Sandy Macrae, the CEO of Sangamo. Thanks so much for joining us today, Sandy.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
A pleasure to be with you.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And for those who may be new to the story, can you provide a 1-minute intro, highlighting your main products and key catalysts.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Delighted to do so. So we have compelling story of clinical products and a remarkable future to come. We're going to talk, I'm sure, about our 3 clinical phase assets, which are either in Phase III or about to go into Phase III in the coming year. We have fabry disease wholly owned with really interesting data that I think is a leading
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot